Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea

NCT00328965 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2010-08-16

No results posted yet for this study

Summary

This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.

Conditions

  • Diabetes Mellitus, Type 2
  • Essential Hypertension

Interventions

DRUG

Lacidipine

Lacidipine 2, 4, 6mg

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, M.D., PH.D. · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2006-05-31
Completion
2006-05-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00328965 on ClinicalTrials.gov